Geoffrey Lynn M.D., D.Phil

Senior Vice President
Barinthus Biotherapeutics

As Senior Vice President at Barinthus Biotherapeutics (NASDAQ, BRNS), Geoffrey Lynn, MD, PhD, is helping to lead innovation and pipeline strategy for developing next generation immunotherapies for cancer, autoimmune and infectious diseases.

Prior to joining Barinthus, Dr. Lynn led Avidea Technologies, Inc. as CEO and founder from its launch at Johns Hopkins to its acquisition by Vaccitech, Plc in 2021. His role at Avidea involved leading financing, team expansion, and operational management including overseeing research and development of a diverse portfolio of immunotherapy candidates supported by varied revenue sources.

Dr. Lynn trained as a visiting scientist in the laboratory of Professor Christopher Jewell at the Fischell Department of Engineering at UMD and as a post-doctoral fellow with Dr. Robert Seder at the Vaccine Research Center of the National Institutes of Health (NIH).

Dr. Lynn received a Medical Degree from Johns Hopkins University and obtained a Ph.D. in Biomedical Engineering from the University of Oxford as an NIH-Oxford-Cambridge Scholar and National Science Foundation Graduate Research Fellow. He received his B.S. in chemistry from Elon University where he was a Goldwater Scholar.